Real-Time Monitoring of the Effectiveness of Six COVID-19 Vaccines against Laboratory-Confirmed COVID-19 in Hungary in 2021 Using the Screening Method.
COVID-19
Hungary
SARS-CoV-2
screening method
surveillance
vaccine effectiveness
waning immunity
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
29 Oct 2022
29 Oct 2022
Historique:
received:
23
09
2022
revised:
21
10
2022
accepted:
25
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
Several studies have reported the waning effectiveness of COVID-19 vaccines. This study aims to demonstrate the applicability of the screening method for estimating vaccine effectiveness (VE) in a pandemic. We report VE in Hungary, estimated with the screening method, in 2021, covering a period of Alpha and the Delta variant, including the booster dose roll-out. Hungary is in a unique position to use six different vaccines in the same population. All vaccines provided a high level of protection initially, which declined over time. While the picture is different in each age group, the waning of immunity is apparent for all vaccines, especially in the younger age groups and the Sinopharm, Sputnik-V, and AstraZeneca vaccines, which performed similarly. This is clearly reversed by booster doses, more prominent for those three vaccines, where the decline in protection is more evident. Overall, two vaccines, Pfizer/BioNTech and Moderna, tend to produce the best results in all age groups, even with waning immunity considered. Using the screening method in future pandemic waves is worthwhile, especially in countries struggling with a lack of resources or when there is a need to deliver VE results within a short timeframe due to urgent decision-making.
Identifiants
pubmed: 36366334
pii: vaccines10111824
doi: 10.3390/vaccines10111824
pmc: PMC9697606
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
Int J Epidemiol. 1993 Aug;22(4):742-6
pubmed: 8225751
Int J Epidemiol. 2007 Jun;36(3):623-31
pubmed: 17403908
Epidemiol Infect. 1987 Oct;99(2):485-99
pubmed: 3678405
Front Immunol. 2022 Jun 23;13:905585
pubmed: 35812442
Front Immunol. 2022 Jul 22;13:919408
pubmed: 35935993
MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1337-1343
pubmed: 34555004
N Engl J Med. 2021 Dec 23;385(26):2413-2420
pubmed: 34879190
Infect Dis Poverty. 2021 Nov 14;10(1):132
pubmed: 34776011
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
N Engl J Med. 2021 Dec 9;385(24):e83
pubmed: 34614327
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
BMJ. 2022 Mar 9;376:e069761
pubmed: 35264324
Nat Med. 2022 May;28(5):1063-1071
pubmed: 35189624
Vaccines (Basel). 2021 Nov 24;9(12):
pubmed: 34960126
Lancet. 2021 Dec 4;398(10316):2093-2100
pubmed: 34756184
BMJ. 2021 Nov 24;375:e067873
pubmed: 34819275
Euro Surveill. 2021 Jul;26(29):
pubmed: 34296676
Clin Microbiol Infect. 2022 Mar;28(3):398-404
pubmed: 34838783
J Glob Health. 2022 Jul 09;12:05025
pubmed: 35802764
Bull World Health Organ. 1985;63(6):1055-68
pubmed: 3879673
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
J Med Virol. 2022 Jul;94(7):2969-2976
pubmed: 35246846
Med J Armed Forces India. 2021 Jul;77:S264-S270
pubmed: 34334892
BMJ. 2021 Dec 15;375:e068848
pubmed: 34911691
J Med Virol. 2022 Oct;94(10):5044-5050
pubmed: 35701379
Vaccines (Basel). 2022 Jun 21;10(7):
pubmed: 35891151